- About UsOur Story, Our Team & Support Information
- What We DoAdvocacy to Achieve the End of AIDS
- Advance HIV/SRH Integration
- Advocate for Access to High-Impact Prevention
- Improve Research Conduct
- Product Innovation & Availability
- Promote Effective HIV Prevention Policy
- Strengthen Global Advocacy Networks
- Track and Translate the Field
- Our FocusInterventions to End the Epidemic
- ResourcesPublications, Infographics, Events & More
- MediaInformation & Resources for the Press
- Our BlogPrevention News & Perspective
March 10, 2020
One of the most anticipated HIV vaccine efficacy trials in the field—HVTN 702, or Uhambo—stopped vaccinations early after a scheduled review showed the vaccine did not offer protection. The news delivered disappointment to the more than 5,000 South Africans who participated in the study, local communities, the field worldwide.
The trial team will continue to follow participants over the next year to monitor safety and answer urgent questions raised by the trial results. In this episode of Px Pulse, HVTN 702 Protocol Co-chair and AVAC Board Member Linda-Gail Bekker explores what the trial team hopes to learn during the follow-up period and how these answers might impact the ongoing pursuit for an HIV vaccine. AVAC’s Regional Stakeholder Engagement Advisor Nandisile Luthuli also joins the conversation to shed light on the trial team’s plans for continuing community engagement, and AVAC’s Director of Research Engagement, Stacey Hannah, talks about the successes of the trial.
Listen
Transcript
Highlights
- What will the HVTN 702 follow-up period tell us? (6:48)
- Implications of HVTN 702 on the field of HIV vaccine research (2:03)
- Next steps for engaging community around HVTN 702 and ongoing HIV vaccine trials (7:23)
- A call to action: applying lessons learned from HVTN 702 community engagement (3:33)
Additional Resources
- NIAID Press Release: Experimental HIV vaccine regimen ineffective in preventing HIV – US NIAD
- Factsheet: Understanding why vaccinations in HVTN 702 Uhambo study were stopped – HVTN
- Global webinar: HVTN 702 updates and next steps – APHA/AVAC
- Vaccine Efficacy Trials Pipeline Graphic – AVAC
- HVTN 702 in the Context of Past, Present and Future HIV Vaccine Research – aidsmap
- Op-ed: Why we're still optimistic even in disappointment about an HIV vaccine – Daily Maverick